News /

Articles Details

Market Intel · Follow

Global insights driving the market strategies of tomorrow.

Johnson & Johnson (JNJ.US) submits regulatory application to FDA for antibody therapy for moderate to severe active ulcerative colitis

Market IntelSunday, Nov 24, 2024 4:10 am ET

1min read

JCI --

Johnson & Johnson (JNJ.US) announced that it has submitted a supplemental Biologics License Application (sBLA) to the US FDA seeking approval of its anti-IL-23 antibody Tremfya (guselkumab) as a subcutaneous (SC) induction regimen for the treatment of adults with moderate to severe active ulcerative colitis (UC).

Comments

Add a public comment...

Post

rbrar33

11/24

Tremfya's approval could boost JNJ stock nicely

SpirituallyAwareDev

11/24

Ulcerative colitis sufferers need options. Guselkumab might just be the magic bullet they've been waiting for. 🚀

Outrageous-Rate-4080

11/24

Riding $JNJ wave; long term hold for me

TeslaCoin1000000

11/24

Could J&J be onto the next big biotech win? Watch how this rollercoaster might affect $JNJ long-term.

Anklebreakers10

11/24

Tremfya's approval would solidify JNJ's foothold in IBD space. Wonder how $TSLA plays into this picture.

tempestlight

11/24

J&J's Tremfya could be a game-changer for UC

themagicalpanda

11/24

Could see JNJ leveraging Tremfya into UC opening more doors. With their track record, it's almost like they're guaranteeing a green light from the FDA. Keep an eye on how the market reacts. This one feels like a solid long-term hold for me.

notbutterface

11/24

Biotech breakthroughs are wild to watch, who's in? 🚀

Direct_Name_2996

11/24

New meds for UC? More potential for pharma plays

VirtualLife76

11/24

With JNJ's drug pipeline, could we see a shift from dividend focus to growth focus? Time to reassess my holdings?

No More Comment

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.

You Can Understand News Better with AI.

Whats the News impact on stock market?

Its impact is

AInvest

Aime Coplilot

Invest Smarter With AI Power.

Open App